ESMO 2022 Conference Coverage
Playback speed
10 seconds
ESMO 2022 on the Phase III JIPANG Study: Final OS Analysis of Pemetrexed/Cisplatin vs. Vinorelbine/Cisplatin for Completely Resected Non-Squamous NSCLC
By
ESMO 2022 Conference Coverage
FEATURING
Kiyotaka Yoh
By
ESMO 2022 Conference Coverage
FEATURING
Kiyotaka Yoh
159 views
October 11, 2022
Comments 0
Login to view comments.
Click here to Login
Lung